J Cardiovasc Imaging.  2019 Jan;27(1):1-10. 10.4250/jcvi.2019.27.e9.

Contemporary Imaging Diagnosis of Cardiac Amyloidosis

• Lee SP
• Park JB
• Kim HK
• Kim YJ
• Grogan M
• Sohn DW

• KMID: 2433758
• DOI: http://doi.org/10.4250/jcvi.2019.27.e9

Abstract

Cardiac amyloidosis is a rare disease that frequently presents as ventricular hypertrophy. However, diagnosis is not always easy or straightforward as there are several myocardial disorders that phenocopy cardiac amyloidosis. Here, we present a narrative review of the current modalities that are actively used or being developed for diagnosis and follow-up of cardiac amyloidosis. Although not all of the findings may be present in those with cardiac amyloidosis, there are some clues in each diagnostic step that help lead to confirmatory diagnosis of cardiac amyloidosis; we believe that cardiologists should be familiar with these clues.

Keyword

Amyloidosis; Echocardiography; Magnetic resonance imaging; Multimodal imaging; Diagnosis

MeSH Terms

Amyloidosis*
Diagnosis*
Echocardiography
Follow-Up Studies
Hypertrophy
Magnetic Resonance Imaging
Multimodal Imaging
Rare Diseases

Figure

• 

  Figure 1 Examples of 12-lead electrocardiograms of cardiac amyloidosis patients. (A, B) Two patients with a similar degree of LV wall thickness, 15 mm. A is a case of cardiac amyloidosis, and B is a case of the concentric form of hypertrophic cardiomyopathy. (A) Despite increased ventricular wall thickness, there is no evidence of ventricular hypertrophy on electrocardiograms. The QRS voltage, especially in the limb leads and the lateral precordial leads, is rather low considering the presence of thickened left ventricular wall. (B) This is in contrast to a significant increase of QRS voltage in patients with hypertrophic cardiomyopathy. (C) A pseudoinfarction pattern in a patient with cardiac amyloidosis. A typical QS wave (red arrows) can be seen in the septal precordial leads and can be misdiagnosed as myocardial infarction.

• 

  Figure 2 Typical echocardiography features in cardiac amyloidosis patients. (A) Thickened LV wall that measures up to 14 mm on parasternal view. (B) Doppler interrogation demonstrates a restrictive filling pattern in the mitral inflow study and very low e′ velocity at the mitral septal annulus. Calculation of E/e′ is estimated to be 30, which indicates high LV filling pressure. (C) An angina patient who developed cardiac amyloidosis after 5 years of percutaneous coronary intervention. The LV wall thickness at the time of coronary intervention was normal, as were the sizes of both atria (left panel). The patient visited the hospital for progressive dyspnea and significant thickening of the ventricular wall, and biatrial enlargement was noted (right panel). Note thickening of the tricuspid valve at the time of diagnosis of cardiac amyloidosis (yellow arrows) that was not evident on initial echocardiography. (D) A representative bull's eye plot of longitudinal strain. Note that the longitudinal strain of the apex is preserved in contrast to those of the other midventricular or basal segments.

• 

  Figure 3 Cardiovascular magnetic resonance (CMR) images of cardiac amyloidosis patients. (A) The pattern of late gadolinium enhancement (LGE) can be diverse in cardiac amyloidosis patients. Although multifocal patchy LGE (A-1) and global subendocardial ring enhancement patterns (A-2) are most common, suboptimal nulling is not unusual (A-3) and even no LGE (A-4) in spite of cardiac amyloidosis on myocardial biopsy. Pericardial effusion is also noted (A-3, yellow arrows). (B) Along with subendocardial LGE in the ventricle, LGE may also be seen in the interatrial septum. (C) Analysis for the presence of intracardiac thrombi in patients with cardiac amyloidosis is important, as in this case in which thrombi were noted at both atria (yellow arrows). (D) Parametric CMR is easy to quantify and gives information on diffuse myocardial change. A typical case of cardiac amyloidosis with an elevated septal native T1 up to 1,550 msec (left panel). A CMR scan of a normal volunteer with a native T1 of 1,150 msec (right panel).

• 

  Figure 4 Nuclear imaging in diagnosis of cardiac amyloidosis and follow-up. (A) A representative image of 99mTc-DPD SPECT in an ATTR cardiac amyloidosis patient. Evident uptake of 99mTc-DPD in the myocardium is noted and is supported by suboptimal nulling on CMR. (B) Uptake of 11C-Pittsburgh B (PiB) compound in a patient with biopsy-proven cardiac amyloidosis (left panel). This compound is specific for amyloid deposits as no 11C-PiB is noted in healthy volunteers (right panel). (C) A significant decrease of 11C-PiB uptake in a patient with cardiac amyloidosis 12 months after chemotherapy and autologous stem cell transplantation (left panel; before chemotherapy, right panel).

Reference

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349:583–596.

2. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992; 79:1817–1822.

3. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013; 161:525–532.

4. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014; 2:113–122.

5. Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983; 75:618–623.

6. Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016; 9:e005066.

7. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017; 38:2879–2887.

8. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015; 32:920–928.

9. Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis. 2013; 106:528–540.

10. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95:535–537.

11. Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:271–280.

12. Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol. 2014; 21:271–283.

13. Lee GY, Kim K, Choi JO, et al. Cardiac amyloidosis without increased left ventricular wall thickness. Mayo Clin Proc. 2014; 89:781–789.

14. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991; 83:808–816.

15. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985; 6:737–743.

16. Bellavia D, Pellikka PA, Al-Zahrani GB, et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr. 2010; 23:643–652.

17. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014; 129:1840–1849.

18. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98:1442–1448.

19. Lee SP, Lee ES, Choi H, et al. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015; 8:50–59.

20. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010; 3:333–342.

21. Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. J Am Coll Cardiol. 2012; 60:1067–1076.

22. Siepen FAD, Bauer R, Voss A, et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2018; 107:158–169.

23. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005; 111:186–193.

24. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 3:155–164.

25. Lee SP, Lee W, Lee JM, et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology. 2015; 274:359–369.

26. Lee H, Park JB, Yoon YE, et al. Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis. JACC Cardiovasc Imaging. 2018; 11:974–983.

27. Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013; 6:34–39.

28. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013; 6:488–497.

29. White JA, Kim HW, Shah D, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014; 7:143–156.

30. Raina S, Lensing SY, Nairooz RS, et al. Prognostic value of late gadolinium enhancement cmr in systemic amyloidosis. JACC Cardiovasc Imaging. 2016; 9:1267–1277.

31. Boynton SJ, Geske JB, Dispenzieri A, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac amyloidosis. JACC Cardiovasc Imaging. 2016; 9:680–686.

32. Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018; 71:2919–2931.

33. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017; 70:466–477.

34. Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014; 7:133–142.

35. Kristen AV, aus dem Siepen F, Scherer K, et al. Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging. Amyloid. 2015; 22:132–141.

36. VanAntwerp JD, O'Mara RE, Pitt MJ, Walsh S. Technetium-99m-diphosphonate accumulation in amyloid. J Nucl Med. 1975; 16:238–240.

37. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46:1076–1084.

38. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6:195–201.

39. Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011; 4:659–670.

40. Kristen AV, Scherer K, Buss S, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014; 7:502–510.

41. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55:306–319.

42. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367:795–804.

43. Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013; 54:213–220.

44. Pilebro B, Arvidsson S, Lindqvist P, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018; 25:240–248.

45. Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014; 41:1652–1662.

46. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016; 57:1733–1739.

47. Park MA, Padera RF, Belanger A, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015; 8:e002954.

48. Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. ¹⁸Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018; 25:1559–1567.